Lutetium-177 labeled therapeutics: Emerging importance for cancer treatment and therapy of chronic disease

Current Radiopharmaceuticals

Volumn 8, Issue 2, 2015, Pages 77-

  Pillai, Ambikalmajan M R ^b  

^a Russ)   (United States)

^b Molecular Group of Companies   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GOLD NANOPARTICLE; LUTETIUM 177; MONOCLONAL ANTIBODY; PEPTIDE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SMALL MOLECULE TRANSPORT AGENT; LUTETIUM; RADIOISOTOPE;

ACUTE DISEASE; CANCER THERAPY; CHRONIC DISEASE; CLINICAL EVALUATION; DOSIMETRY; EDITORIAL; HUMAN; ISOTOPE LABELING; NEOPLASM; NUCLEAR MEDICINE; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; NEOPLASMS; PROCEDURES;

CHRONIC DISEASE; HUMANS; LUTETIUM; NEOPLASMS; NUCLEAR MEDICINE; RADIOISOTOPES;

EID: 84940903112     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471008666150312124009     Document Type: Editorial

References (0)